Furthermore, inhibiting the RNA binding protein IGF2BP3 may also increase the efficacy of MIs in MLLr leukemias, as knocking down IGF2BP3 enhances the differentiation of MLL-AF4 leukemia cells following treatment with MI-503 [205]. Here, IGF2BP3 is linked to leukemia.